SCHEMBL429150

SCHEMBL429150

Cc1cccc(C)c1NC=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
TSHR P16473 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 4/20 0.38
CYP1A2 P05177 3/20 0.38
MEN1 O00255 3/20 0.38
CYP2C9 P11712 2/20 0.38
NFKB1 P19838 1/20 0.38
CYP2C19 P33261 1/20 0.38
CYP2A6 P11509 1/20 0.38
POLB P06746 3/20 0.37
ACHE P22303 1/20 0.36
MAPT P10636 2/20 0.36
SCN3A Q9NY46 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9840547 0.87 TSHR (0.39) ALDH1A1TSHRL3MBTL1KMT2ACYP1A2
SCHEMBL7528740 0.85 GAA (0.46) ALDH1A1L3MBTL1KMT2AMEN1POLB
SCHEMBL9801002 0.83 PTGS2 (0.46) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL7536495 0.83 PTGS2 (0.46) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL1911387 0.82 CYP1A2 (0.47) ALDH1A1L3MBTL1KMT2ACYP1A2CYP2C19
SCHEMBL7223406 0.82 GABRA1 (0.46) ALDH1A1TSHRL3MBTL1KMT2ACYP1A2
SCHEMBL7532751 0.82 MAPK1 (0.47) TSHRL3MBTL1KMT2ACYP1A2MEN1
SCHEMBL9511883 0.80 POLB (0.56) ALDH1A1L3MBTL1KMT2ACYP1A2MEN1
SCHEMBL3045742 0.80 TSHR (0.56) ALDH1A1TSHRL3MBTL1KMT2AMEN1
SCHEMBL7692381 0.79 MEN1 (0.42) ALDH1A1TSHRL3MBTL1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US claimed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 EP claimed
EP-0358749-A1 1,4-SUBSTITUTED-2,3,5,6-TETRAHYDRO 1,3,6]TRIAZOCINO 1,2-a]BENZIMIDAZOLES AND INTERMEDIATES THEREFOR AMERICAN HOME PRODUCTS CORPORATION (US) 1990-03-21 EP claimed
US-4882323-A ANTIARRYTHMIA AGENT INTERMEDIATES AMERICAN HOME PRODUCTS (US) 1989-11-21 US claimed
WO-1989008111-A1 1,4-SUBSTITUTED-2,3,5,6-TETRAHYDRO[1,3,6]TRIAZOCINO[1,2-a]BENZIMIDAZOLES AND INTERMEDIATES THEREFOR AMERICAN HOME PRODUCTS CORPORATION (US) 1989-09-08 WO claimed
US-4801706-A ANTIARRHYTHMIA HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1989-01-31 US claimed
US-20250154353-A1 RESIN COMPOSITION AND ARTICLE MADE THEREFROM ELITE ELECTRONIC MATERIAL (KUNSHAN) CO., LTD. (CN) 2025-05-15 US disclosed
WO-2021087113-A1 LOCAL ANESTHETICS WITH SELECTIVE-SENSORY NERVE BLOCKADE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-05-06 WO disclosed
US-10233157-B2 SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-03-19 US disclosed
EP-3444031-A1 HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) 2019-02-20 EP disclosed
EP-2755944-B1 BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2017-06-14 EP disclosed
EP-0337819-A1 Thiazole derivatives, their preparation and their use in the treatment of diabetes complications Sankyo Company Limited (JP) 1989-10-18 EP disclosed
US-4801706-A ANTIARRHYTHMIA HYPOTENSIVE AMERICAN HOME PRODUCTS CORPORATION (US) 1989-01-31 US disclosed
EP-0073326-B1 PROCESS FOR PREPARING NITRILES FROM FORMAMIDES BASF Aktiengesellschaft (DE) 1985-10-23 EP disclosed
EP-0073326-A1 Process for preparing nitriles from formamides BASF Aktiengesellschaft (DE) 1983-03-09 EP disclosed
US-4178387-A ADMINISTERING AMIDINOUREAS WILLIAM H. RORER, INC. (US) 1979-12-11 US disclosed
US-4147804-A ANTIARRHYTHMIA AGENTS WILLIAM H. RORER, INC. (US) 1979-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233157-B2 SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder SIK1, SIK2, SGK1 ALDH1A1 4501/4885TSHR 4596/4885L3MBTL1 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.